

April 24, 2025

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal
Street Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: Regulation 76 of Securities and Exchange Board of India (Depositories & Participants) Regulations, 2018 read with SEBI Master Circular no. SEBI/HO/MRD/MRD-PoD-1/P/CIR/2024/168 dated December 03, 2024

Sub: Reconciliation of Share Capital Audit Report for Quarter-IV of Financial Year 2024-25, ended on March 31, 2025

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 76 of Securities and Exchange Board of India (Depositories & Participants) Regulations, 2018, as amended, read with SEBI Master Circular no. SEBI/HO/MRD/MRD-PoD-1/P/CIR/2024/168 for Depositories, dated December 03, 2024, kindly find enclosed herewith copy of the Reconciliation of Share Capital Audit Report issued by M/s. Brajesh Kumar & Associates, Practicing Company Secretary, along with the Reconciliation Statement issued by M/s. Abhipra Capital Limited, Registrar & Share Transfer Agent of Orchid Pharma Limited, for the Quarter-IV of Financial Year 2024-25, ended on March 31, 2025.

You are requested to take the above information on record.

Thanking You,

For **Orchid Pharma Limited**




Kapil Dayya
Company Secretary & Compliance Officer
M. No: F10698

Encl.: As above

BRAJESH KUMAR & ASSOCIATES

COMPANY SECRETARIES

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

To,

The Board of Directors,

ORCHID PHARMA LIMITED

Plot Nos. 121-128, 128A-133, 138-151,
159-164, SIDCO Industrial Estate, Alathur,
Chengalpattu Dist.- 603110, Tamil Nadu, India

We have examined the Register of Members, beneficiary details furnished by the Depositories and other records/ documents maintained by Orchid Pharma Limited (hereinafter referred to as "the Company") and its Registrar and Transfer Agent, M/s. Abhipra Capital Limited, for issuing this certificate, in accordance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, as amended.

To the best of our knowledge and according to the information & explanations furnished to us by the Company followed by such verification as considered necessary, we hereby certify the following:

1.	For the Quarter ended	March 31, 2025	
2.	ISIN	INE191A01027	
3.	Face Value	Rs.10/-	
4.	Name of the Company	Orchid Pharma Limited	
5.	Registered Office Address	Plot Nos. 121-128, 128A-133, 138-151,159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Dist.- 603110, Tamil Nadu, India	
6.	Correspondence Address	Same as above	
7.	Telephone	Phone: (91)-44- 2744 4471/72/73	
8.	Email address	cs@orchidpharma.com	
9.	Name of the stock exchanges where the Company securities are listed:	BSE Limited and National Stock Exchange of India Limited	
10.	Issued Capital	Number of shares	% of Total Issued Capital
		5,07,19,105	100

BRAJESH KUMAR & ASSOCIATES

COMPANY SECRETARIES

11.	Listed Capital (Exchange-wise)	<table><tr><td>NSE</td><td>5,07,19,105</td><td>100</td></tr><tr><td>BSE</td><td>5,07,19,105</td><td>100</td></tr></table>					NSE	5,07,19,105	100	BSE	5,07,19,105	100
NSE	5,07,19,105	100										
BSE	5,07,19,105	100										
12.	Held in dematerialized form in CDSL	3,94,73,985		77.83								
13.	Held in dematerialized form in NSDL	1,12,41,608		22.16								
14.	Physical	3,512		0.01								
15.	Total No. of shares (12+13+14)	5,07,19,105		100								
16.	Reasons for difference if any, between (10&11) , (10&15) , (11&15) :	NIL										
17.	Certifying the details of changes in share capital during the quarter under consideration as per table below :											
	Particulars	No. of shares	Applied /Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for SE (Specify Names)					
	NA	NIL	NA	NA	NA	NA	NA					
18.	Register of Members is updated (Yes / No) If not, updated up to which date.			YES								
19.	Reference of previous quarter with regards to excess dematerialized shares, if any			NA								
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?			NA								
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:											
	Total no. of Demat requests	No. of requests		No. of shares		Reasons for delay						
	Confirmed after 21 days	NIL		NIL		NA						
	Pending for more than 21 days	NIL		NIL		NA						
22.	Name and Telephone no. of the Compliance Officer of the Company			Kapil Dayya Company Secretary & Compliance Officer Orchid Pharma Limited Plot Nos. 121 – 128, 128A – 133, 138 – 151, 159 – 164, SIDCO Industrial Estate, Alathur.								

BRAJESH KUMAR & ASSOCIATES
COMPANY SECRETARIES

		Chengalpattu District – 603110, Tamil Nadu. Phone: (91)-44- 2744 4471/72/73; E-mail: cs@orchidpharma.com
23.	Name, Address, Tel. No. and Regn. No. of the Auditor	Brajesh Kumar Company Secretary in Practice Sunrise Apartment, E-73/74/75, Second Floor (LHS) Gali No.-10, Om Vihar Extension, Uttam Nagar, New Delhi-110059 F.C.S.:6965 C.P. No. 7497 M-9818988730 E-mail: brajeshcs@gmail.com
24.	Appointment of Common Agency for share registry work	Abhipra Capital Limited Abhipra Complex A-387, Dilkhush, Industrial Area, G.T. Karnal Road, Azadpur, Delhi- 110033 Phone: +91-11-42390783 Email: rta@abhipra.com
25.	Any other details that the auditor may like to provide:	NIL

Note: Abbreviations: NA stands for Not Applicable

Place: New Delhi
Date: 09/04/2025

For Brajesh Kumar & Associates



Practising Company Secretary
M. No. F6965 | CP: 7497
PR: 5461/2024
UIN: S2007DE093900

UDIN: F006965G000070611



Abhipra Capital Limited

(Category – I, Registrar and Transfer Agent)

Abhipra Complex A-387, Dilkhush Indl Area,

G.T. Karnal Road, Azadpur, Delhi-110033

Phone: +91-11-42390783 | Email: rta@abhipra.com

Website: www.abhipra.com | CIN: U74899DL1994PLC061802

Ref No :

Date: 05-Apr-2025

To,
Orchid Pharma Limited
Plot Nos. 121 – 128, 128a – 133, 138 – 151, 159 – 164,
Sidco Industrial Estate, Alathur,
Chengalpattu District – 603110, Tamil Nadu

ISIN No: INE191A01027

Pursuant to SEBI circular D&CC/FITTC/CIR-16/2002 dated 31st December, 2002, we hereby confirm as under :

1. Details of Shareholding as on 31-Mar-2025 :

	Quantity of Equity Shares	Percentage (%)
NSDL	1,12,41,608	22.1644
CDSL	3,94,73,985	77.8286
Physical	3,512	0.0069
Total	5,07,19,105	

2. Details of the Requests received during the period from 01-Jan-2025 to 31-Mar-2025

S No	Particulars	No of requests pending	No of shares pending	No of requests accepted	No of shares accepted	No of requests rejected	No of Shares rejected
1	Transfer requests	0	0	0	0	0	0
2	Requests received for split	0	0	0	0	0	0
3	Requests received for consolidation	0	0	0	0	0	0
4	Requests received for sub-division	0	0	0	0	0	0
5	Requests received for duplicate	0	0	0	0	0	0



Abhipra Capital Limited

(Category – I, Registrar and Transfer Agent)

Abhipra Complex A-387, Dilkhush Indl Area,

G.T. Karnal Road, Azadpur, Delhi-110033

Phone: +91-11-42390783 | Email: rta@abhipra.com

Website: www.abhipra.com | CIN: U74899DL1994PLC061802

S No	Particulars	No of requests pending	No of shares pending	No of requests accepted	No of shares accepted	No of requests rejected	No of Shares rejected
6	Requests received for transmission	0	0	0	0	0	0
7	Demat requests (NSDL)	0	0	0	0	0	0
8	Demat requests (CDSL)	0	0	0	0	0	0
9	Remat requests (NSDL)	0	0	0	0	0	0
10	Remat requests (CDSL)	0	0	0	0	0	0

3. That in terms of Para(2) of the circular the register of members have been updated as on 31-Mar-2025.

4. That in terms of Para (3) of the circular all the dematerialization requests have been processed and confirmed within 21 days and no request is pending for more than 21 days from the date of receipt.

This is for your information and record.

Thanking you,

For **Abhipra Capital Limited**
ABHINAV
AGGARWAL
Digitally signed by
ABHINAV AGGARWAL
Date: 2025.04.07
12:26:33 +05'30'
Abhinav Aggarwal
(Director)